MENU
IBRN
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
IBRN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRN with price predictions
Aug 21, 2026

Momentum Indicator for IBRN turns positive, indicating new upward trend

IBRN saw its Momentum Indicator move above the 0 level on August 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned positive. In of the 73 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for IBRN just turned positive on August 07, 2026. Looking at past instances where IBRN's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

IBRN moved above its 50-day moving average on August 04, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRN advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IBRN moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBRN broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBRN entered a downward trend on August 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 5.31B. The market cap for tickers in the group ranges from 107M to 65.95B. ARGX holds the highest valuation in this group at 65.95B. The lowest valued company is SAVA at 107M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 79%. For the same ETF, the average monthly price growth was 118%, and the average quarterly price growth was 206%. AMLX experienced the highest price growth at 79%, while IART experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was -45%. For the same stocks of the ETF, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 72
Price Growth Rating: 45
SMR Rating: 87
Profit Risk Rating: 80
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com